Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Essen Biotech

ClinicalTrials.gov lists Essen Biotech as lead sponsor of 17 trials. It has 164 active development programs and 4 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 58 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Active development programs Active development programs 164 Approved assets Approved assets 4 Latest dated events Latest dated events 17 Biomarker capability evidence Biomarker capability evidence 42 Disease areas Disease areas 58 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Active development programs Active development programs 164 Approved assets Approved assets 4 Latest dated events Latest dated events 17 Biomarker capability evidence Biomarker capability evidence 42

Rows recorded per section (log scale)

18 sections measured, none recorded

This page covers Essen Biotech: 17 lead-sponsored trials and 0 legal-entity registrations.

Get the Essen Biotech report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (58)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lymphoma 4
Breast Neoplasms 3
Colorectal Neoplasms 3
Glioblastoma 3
Glioma 3

Showing 5 of 58 disease areas.

Start your 14-day trial Email me the first 50 disease areas as a PDF

Trials by start year as sponsor or collaborator (3)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 2
2025 4
2024 11

No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 17 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (164)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Dual-Target Antigen-Selected CAR-NK Carcinoma, Non-Small-Cell Lung Phase 1/2 1
Dual-Target Antigen-Selected CAR-NK Glioblastoma Phase 1/2 1
Dual-Target Antigen-Selected CAR-NK Glioma Phase 1/2 1
Dual-Target Antigen-Selected CAR-NK Carcinoma, Hepatocellular Phase 1/2 1
Dual-Target Antigen-Selected CAR-NK Breast Neoplasms Phase 1/2 1

Showing 5 of 164 active programs.

Start your 14-day trial Email me the first 50 active programs as a PDF

Approved assets (4)

Shown in this order: max phase first.

Approved assets
Drug Trials
Interleukin 2 5
PEMBROLIZUMAB 5
FLUDARABINE 5
CYCLOPHOSPHAMIDE 3

Latest dated events (17)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-02-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-02-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-05-29 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04-29 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04-29 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 17 events.

Start your 14-day trial Email me all 17 events as a PDF

Biomarker capability evidence (42)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
CD19 Trial sponsor Named in trial inclusion criteria
CD19 Trial sponsor Named in trial inclusion criteria
CD22 Trial sponsor Named in trial inclusion criteria
CD33 Trial sponsor Named in trial inclusion criteria
CD5 Trial sponsor Named in trial inclusion criteria

Showing 5 of 42 evidence rows.

Start your 14-day trial Email me all 42 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.